BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 22, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lotrel amlodipine/benazepril: Additional Phase III data

Additional data from the double-blind, U.S. and Scandinavian Phase III ACCOMPLISH trial in 11,506 patients showed that Lotrel led to significantly less progression of CKD vs. benazepril plus hydrochlorothiazide (2% vs. 3.7%, p<0.0001). Lotrel also significantly reduced the combined endpoints of...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >